ES2131842T3 - Compuestos de triazol y su empleo como ligandos de dopamina-d3. - Google Patents

Compuestos de triazol y su empleo como ligandos de dopamina-d3.

Info

Publication number
ES2131842T3
ES2131842T3 ES95926895T ES95926895T ES2131842T3 ES 2131842 T3 ES2131842 T3 ES 2131842T3 ES 95926895 T ES95926895 T ES 95926895T ES 95926895 T ES95926895 T ES 95926895T ES 2131842 T3 ES2131842 T3 ES 2131842T3
Authority
ES
Spain
Prior art keywords
dopamine
pct
triazole compounds
leagues
sec
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95926895T
Other languages
English (en)
Inventor
Beate Hellendahl
Annegret Lansky
Rainer Munschauer
Siegfried Bialojan
Liliane Unger
Hans-Jurgen Teschendorf
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BASF SE
Original Assignee
BASF SE
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=6523323&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2131842(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by BASF SE filed Critical BASF SE
Application granted granted Critical
Publication of ES2131842T3 publication Critical patent/ES2131842T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/26Psychostimulants, e.g. nicotine, cocaine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/101,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/12Oxygen or sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/101,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/14Nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

LA PRESENTE INVENCION TRATA DE COMPUESTOS DE TRIAZOL DE FORMULA (I), EN DONDE R{SUP,1} Y R{SUP,2} SON H O DIFERENTES SUSTITUYENTES, A ES UN GRUPO BIVALENTE, B ES UN RADICAL DE FORMULA (A), (B) O (C) ES FENILO, PIRIDILO, PIRIMIDILO O TRIAZINILO OPCIONALMENTE SUSTITUIDO. LOS COMPUESTOS DE LA INVENCION POSEEN UNA ELEVADA AFINIDAD CON EL RECEPTOR D{SUB,3} DE LA DOPAMINA, Y SE UTILIZAN POR TANTO PARA EL TRATAMIENTO DE ENFERMEDADES, QUE TIENEN QUE VER CON LOS LIGANDOS DEL D{SUB,3} DE LA DOPAMINA.
ES95926895T 1994-07-15 1995-07-14 Compuestos de triazol y su empleo como ligandos de dopamina-d3. Expired - Lifetime ES2131842T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4425144A DE4425144A1 (de) 1994-07-15 1994-07-15 Triazolverbindungen und deren Verwendung

Publications (1)

Publication Number Publication Date
ES2131842T3 true ES2131842T3 (es) 1999-08-01

Family

ID=6523323

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95926895T Expired - Lifetime ES2131842T3 (es) 1994-07-15 1995-07-14 Compuestos de triazol y su empleo como ligandos de dopamina-d3.

Country Status (23)

Country Link
US (1) US6124294A (es)
EP (1) EP0772604B1 (es)
KR (1) KR100379196B1 (es)
CN (1) CN1068314C (es)
AT (1) ATE179703T1 (es)
AU (1) AU703889B2 (es)
BG (1) BG63500B1 (es)
BR (1) BR9508294A (es)
CA (1) CA2195243C (es)
CZ (1) CZ292625B6 (es)
DE (2) DE4425144A1 (es)
DK (1) DK0772604T3 (es)
ES (1) ES2131842T3 (es)
FI (1) FI970147A (es)
GR (1) GR3030371T3 (es)
HU (1) HU225961B1 (es)
IL (1) IL114598A (es)
NO (1) NO315320B1 (es)
NZ (1) NZ290387A (es)
RU (1) RU2167869C2 (es)
SI (1) SI9520083A (es)
WO (1) WO1996002520A1 (es)
ZA (1) ZA955867B (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19600934A1 (de) 1996-01-12 1997-07-17 Basf Ag Substituierte Aza- und Diazacycloheptan- und Cyclooctanverbindungen und deren Verwendung
DE19728996A1 (de) * 1997-07-07 1999-01-14 Basf Ag Triazolverbindungen und deren Verwendung
HUP0104280A3 (en) 1998-10-08 2002-07-29 Smithkline Beecham Plc Tetrahydrobenzazepine derivatives useful as modulators of dopamine d3 receptors, process for their preparation, medicaments containing them
AR022230A1 (es) * 1999-01-12 2002-09-04 Abbott Gmbh & Co Kg Compuestos de triazol, composicion farmaceutica que los comprende y uso de los mismos para preparar dicha composicion
EP1223932A4 (en) 1999-10-01 2003-01-15 Smithkline Beecham Corp COMPOUNDS AND METHODS
ES2311012T3 (es) * 2000-03-27 2009-02-01 ABBOTT GMBH & CO. KG Ligandos del receptor d3 de la dopamina para el tratamiento de la adiccion.
DE10109867A1 (de) * 2001-03-01 2002-09-05 Abbott Gmbh & Co Kg Verwendung von Triazolverbindungen zur Prophylaxe und Therapie neurodegenerativer Erkrankungen, Hirntrauma und zerebraler Ischämie
DE10109866A1 (de) * 2001-03-01 2002-09-05 Abbott Gmbh & Co Kg Triazolverbindungen und deren Verwendung zur Prophylaxe und Therapie neurodegenerativer Erkrankungen, Hirntrauma und zerebraler Ischämie
US7605259B2 (en) 2002-09-14 2009-10-20 University Of North Texas Health Science Center At Fort Worth Structurally rigid dopamine d3 receptor selective ligands and process for making them
CZ300500B6 (cs) * 2002-11-11 2009-06-03 Zpusob uzavírání špic v pletacím stroji
DE10304870A1 (de) 2003-02-06 2004-08-19 Abbott Gmbh & Co. Kg Triazolverbindungen und ihre therapeutische Verwendung
JP2004359689A (ja) * 2003-06-05 2004-12-24 Abbott Gmbh & Co Kg ドーパミンd3受容体のモジュレーションに反応する障害の治療に適するトリアゾール化合物
US6919342B2 (en) 2003-06-05 2005-07-19 Abbott Gmbh & Co. Kg Triazole compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor
DE10358004A1 (de) 2003-12-11 2005-07-14 Abbott Gmbh & Co. Kg Ketolactam-Verbindungen und ihre Verwendung
US20050137186A1 (en) 2003-12-18 2005-06-23 Abbott Gmbh & Co. Kg. Tetrahydrobenzazepines and their use
US8207160B2 (en) 2003-12-18 2012-06-26 Abbott Gmbh & Co. Kg Tetrahydrobenzazepines and their use in he modulation of the dopamine D3 receptor
DE102004027358A1 (de) 2004-06-04 2005-12-29 Abbott Gmbh & Co. Kg Pyrimidinverbindungen und ihre Verwendung
ATE452134T1 (de) 2004-08-09 2010-01-15 Abbott Gmbh & Co Kg Zur behandlung von auf eine modulation des dopamin-d3-rezeptors ansprechende erkrankungen geeignete 4-piperazinylpyrimidinverbindungen
US8101754B2 (en) * 2004-12-02 2012-01-24 Abbott Gmbh & Co. Kg Triazole compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor
GB0507680D0 (en) 2005-04-15 2005-05-25 Glaxo Group Ltd Compounds
GB0512099D0 (en) * 2005-06-14 2005-07-20 Glaxo Group Ltd Compounds
WO2009019472A1 (en) 2007-08-07 2009-02-12 Prosarix Limited 1, 2, 4 -triazole derivatives as serotonergic modulators
PA8802101A1 (es) 2007-11-02 2009-08-26 Abbott Gmbh & Co Kg Compuestos de 1,2,4-3,5-diona adecuados para el tratamiento de trastornos que responden a la modulación del receptor de dopamina d3
HUE031419T2 (en) * 2008-07-03 2017-07-28 Astellas Pharma Inc Triazole derivative or salt

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1053085A (es) * 1964-03-26
US4338453A (en) * 1980-09-17 1982-07-06 The Upjohn Company Aminoalkyl-1,2,4-triazoles
US4408049A (en) * 1980-09-17 1983-10-04 The Upjohn Company Substituted piperazinyl-1,2,4-triazoles
US4487773A (en) * 1981-03-16 1984-12-11 Mead Johnson & Company 1,2,4-Triazol-3-one antidepressants
US4577020A (en) * 1983-01-25 1986-03-18 The Upjohn Company Aminoalkyl and aminoalkenyl triazoles as anti-psychotic agents
US4575555A (en) * 1983-06-29 1986-03-11 Mead Johnson & Company 4-(3-Chlorophenyl)-1,2,3,6-tetrahydropyridine derivative
US4613600A (en) * 1983-09-30 1986-09-23 Mead Johnson & Company Antidepressant 1,2,4-triazolone compounds
FR2580648B1 (fr) * 1985-04-17 1987-05-15 Adir Nouveaux derives du triazole, leur procede de preparation et les compositions pharmaceutiques les renfermant
FR2601952B1 (fr) * 1986-07-23 1988-11-25 Carpibem Nouveaux derives amino alkyl thio de triazolopyridine ou triazoloquinoline, leurs procedes de preparation, medicaments les contenant, utiles notamment comme antalgiques
FR2672052B1 (fr) * 1991-01-28 1995-05-24 Esteve Labor Dr Derives d'aryl (ou heteroaryl)-piperazinyl-alkyl-azoles, leur preparation et leur application en tant que medicaments.
GB9021535D0 (en) * 1990-10-03 1990-11-14 Wyeth John & Brother Ltd Piperazine derivatives
US5256664A (en) * 1992-04-28 1993-10-26 Bristol-Myers Squibb Company Antidepressant 3-halophenylpiperazinylpropyl derivatives of substituted triazolones and triazoldiones

Also Published As

Publication number Publication date
JP4114950B2 (ja) 2008-07-09
CN1152919A (zh) 1997-06-25
JPH10502914A (ja) 1998-03-17
US6124294A (en) 2000-09-26
HU225961B1 (en) 2008-01-28
SI9520083A (en) 1997-10-31
KR970704710A (ko) 1997-09-06
HU9700109D0 (en) 1997-02-28
NO315320B1 (no) 2003-08-18
RU2167869C2 (ru) 2001-05-27
NO970161L (no) 1997-03-14
CA2195243A1 (en) 1996-02-01
BG101113A (en) 1998-04-30
AU3111395A (en) 1996-02-16
IL114598A (en) 1999-12-22
BG63500B1 (bg) 2002-03-29
NZ290387A (en) 1999-02-25
CZ292625B6 (cs) 2003-11-12
DK0772604T3 (da) 1999-11-01
HUT77128A (hu) 1998-03-02
BR9508294A (pt) 1997-12-30
FI970147A0 (fi) 1997-01-14
KR100379196B1 (ko) 2003-06-11
WO1996002520A1 (de) 1996-02-01
AU703889B2 (en) 1999-04-01
FI970147A (fi) 1997-01-14
DE59505853D1 (de) 1999-06-10
GR3030371T3 (en) 1999-09-30
DE4425144A1 (de) 1996-01-18
CA2195243C (en) 2006-05-30
IL114598A0 (en) 1995-11-27
EP0772604A1 (de) 1997-05-14
CN1068314C (zh) 2001-07-11
NO970161D0 (no) 1997-01-14
EP0772604B1 (de) 1999-05-06
CZ9797A3 (en) 1997-08-13
ZA955867B (en) 1997-01-14
ATE179703T1 (de) 1999-05-15

Similar Documents

Publication Publication Date Title
ES2131842T3 (es) Compuestos de triazol y su empleo como ligandos de dopamina-d3.
ES2196072T3 (es) Empleo de compuestos heterociclicos como ligandos de dopamina-d3.
NO970162L (no) Substituerte pyrimidinforbindelser og anvendelse derav
FI970149A0 (fi) Tiatsoli- ja tiadiatsoliyhdisteiden käyttö D3-reseptoriligandeina

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 772604

Country of ref document: ES